Substance/medication-induced bipolar and related disorder (SMIBD) describes a manic or hypomanic syndrome that emerges during or shortly after intoxication, withdrawal, or therapeutic exposure to an agent capable of producing the picture, and that is judged to be a direct physiological consequence of that agent rather than a primary mood disorder. It sits in DSM-5-TR within the Bipolar and Related Disorders chapter and is mirrored in ICD-11 as a substance-induced mood disorder under the relevant substance class. The clinical task is twofold: recognize the syndrome as phenomenologically indistinguishable from primary mania at the bedside, and resist anchoring on a primary Bipolar I disorder diagnosis until a careful temporal and pharmacologic review is complete. Stimulants, corticosteroids, antidepressants in vulnerable patients, dopamine agonists, and select antimicrobials are the usual culprits. Most episodes resolve within days to weeks of removing the offending agent, but a meaningful minority go on to declare a primary bipolar diathesis, which has direct implications for long-term mood stabilization. The bedside bottom line: treat the acute manic syndrome, identify and remove the agent, and reassess the diagnosis after a drug-free interval before committing the patient to lifelong mood stabilizer therapy.

Population-based prevalence figures for SMIBD are scarce because the diagnosis requires longitudinal follow-up to distinguish from primary bipolar disorder, and most epidemiologic instruments collapse the two. The clinically useful numbers come from clinic and registry samples.

Prevalence and incidence

• Among first-episode mania admissions, between 8% and 26% are attributed to a substance or medication depending on the cohort and ascertainment method. ^1-2
• In the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), substance-induced mood disorders were uncommon (<1% lifetime) but markedly elevated risk of subsequent primary mood disorder. ³
• Antidepressant-associated mania occurs in roughly 8-15% of bipolar-spectrum patients exposed to antidepressant monotherapy and in a smaller fraction (<1-2%) of unipolar depressed patients. ^4-5
• Corticosteroid-induced mood symptoms occur in approximately 15-30% of patients on prednisone-equivalent doses above 40 mg/day, with frank mania or hypomania in roughly 5-10%. ⁶

Demographic patterns

• Onset distribution mirrors the exposure distribution rather than the bimodal age curve of primary bipolar disorder; stimulant-induced episodes cluster in young adults, steroid-induced episodes follow the underlying medical illness across the lifespan. ^1,7
• Male predominance in stimulant- and alcohol-related cases reflects substance-use base rates; iatrogenic cases (steroids, levodopa) track the demographics of the prescribed indication. ^7-8

Risk factors

• Family history of bipolar disorder is the strongest predictor of antidepressant-emergent mania and is associated with conversion to a primary bipolar diagnosis on follow-up. ^4,9
• Prior depressive episodes with mixed features, early age of depression onset, and bipolar-spectrum traits raise the risk of antidepressant-induced switch. ^4,9
• Higher steroid dose, rapid dose escalation, and prior steroid-related neuropsychiatric reactions predict corticosteroid-induced mania. ⁶
• Polysubstance use, particularly stimulants combined with sleep deprivation, is a common precipitant in emergency department presentations. ¹⁰

The causal logic of SMIBD is mechanistic rather than syndromic: agents that increase synaptic monoamines, disrupt sleep, or alter HPA-axis tone can drive a manic phenotype in susceptible individuals. The neurobiology overlaps substantially with primary mania, which is part of why phenotypic differentiation at the bedside is unreliable.

Neurobiology

• Excess dopaminergic transmission in mesolimbic and prefrontal circuits is a final common pathway for stimulant-induced and dopamine-agonist-induced mania. ¹¹
• Serotonergic and noradrenergic potentiation underlies antidepressant-induced switch, with greater risk attributed to dual-action and tricyclic agents than to SSRIs. ^4,12
• Glucocorticoid-driven dysregulation of the hypothalamic-pituitary-adrenal axis and hippocampal mineralocorticoid/glucocorticoid receptor balance underlies corticosteroid-induced mood syndromes. ^6,13
• Sleep deprivation, common to many precipitants, is itself a potent manicogenic stimulus and frequently mediates the final clinical picture. ¹⁴

Genetic and individual susceptibility

• Polygenic risk for bipolar disorder predicts antidepressant-emergent mania in pharmacogenetic cohorts, supporting a shared diathesis model. ^9,15
• CYP2D6 and CYP3A4 variants modulate plasma levels of relevant substrates and can convert standard doses into supratherapeutic exposure. ¹⁶

Common offending agents

• Stimulants: cocaine, methamphetamine, prescription amphetamines, methylphenidate. ^10,17
• Antidepressants: tricyclics, venlafaxine at high dose, and bupropion carry higher switch risk than SSRIs. ^4,12
• Corticosteroids: prednisone, dexamethasone, ACTH; risk is dose-dependent. ⁶
• Dopaminergic agents: levodopa, pramipexole, ropinirole, amantadine. ¹⁸
• Antimicrobials: isoniazid, efavirenz, fluoroquinolones, and clarithromycin have well-documented case-series associations. ^19-20
• Other: anabolic steroids, hallucinogens during intoxication, MDMA, synthetic cannabinoids, and rarely interferon-alpha. ^21-22
• Withdrawal-related: alcohol, sedative-hypnotic, and opioid withdrawal can produce hyperarousal states that mimic mania. ²³

DSM-5-TR places SMIBD within the Bipolar and Related Disorders chapter alongside primary Bipolar I, Bipolar II, and cyclothymic disorder. The architecture of the criteria mirrors the broader substance/medication-induced mental disorders framework.

Core DSM-5-TR criteria

• A prominent and persistent disturbance in mood characterized by elevated, expansive, or irritable mood, with or without depressed mood or anhedonia, dominates the clinical picture. ²⁴
• Evidence from history, examination, or laboratory findings supports both that the symptoms emerged during or soon after substance intoxication, withdrawal, or exposure to a medication, and that the involved substance or medication is capable of producing the symptoms. ²⁴
• The disturbance is not better explained by an independent bipolar or related disorder. Independence is supported by: symptoms preceding the substance or medication exposure; symptoms persisting for a substantial period (commonly cited as about one month) after acute withdrawal or intoxication; or other evidence of an independent non-substance-induced disorder, such as a clear history of recurrent non-substance-related episodes. ²⁴
• The disturbance does not occur exclusively during the course of a delirium. ²⁴
• The disturbance causes clinically significant distress or impairment. ²⁴

Specifiers and coding

• Specify "with onset during intoxication" or "with onset during withdrawal" depending on temporal relationship. ²⁴
• Specify "with onset after medication use" when the syndrome follows therapeutic exposure rather than substance misuse. ²⁴
• Code specific to the substance class (alcohol-induced, cocaine-induced, amphetamine-induced, etc.) using the relevant ICD-10-CM substance code with mood disturbance qualifier. ²⁴
• Severity is not formally specified for SMIBD as it is for primary bipolar disorder; document severity in narrative form. ²⁴

ICD-11 differences

• ICD-11 categorizes substance-induced mood disorders under each substance class within Disorders Due to Substance Use (chapter 06), not within the mood disorders chapter, with separate codes for substance-induced manic, depressive, and mixed presentations. ²⁵
• ICD-11 does not require the one-month persistence threshold by default; the clinician documents the temporal relationship and judges whether the syndrome is independent. ²⁵

The clinical picture is phenomenologically indistinguishable from primary mania or hypomania, which is why pattern recognition without a careful exposure history will fail. The differentiating signal is temporal, not symptomatic.

Symptom clusters

• Elevated, expansive, or irritable mood with increased energy or goal-directed activity is the gateway feature, mirroring DSM-5-TR mania criterion A. ²⁴
• Decreased need for sleep, pressured speech, flight of ideas, distractibility, grandiosity, and risky behavior populate the symptom list as in primary mania. ²⁴
• Psychotic features (grandiose or paranoid delusions, hallucinations) are common in stimulant-induced and steroid-induced presentations and do not by themselves distinguish secondary from primary mania. ^10,26

Course features that suggest a substance/medication etiology:

• Tight temporal coupling: symptoms begin within hours to days of exposure or dose escalation, and remit within days to weeks of discontinuation. ^1,6
• Atypical age of first onset: a first manic episode after age 40 should raise the index of suspicion for secondary causes including substance and medication etiologies. ²⁷
• Prominent confusion or perceptual disturbance, especially with steroids or anticholinergic agents, suggests a secondary etiology and demands delirium screening. ¹³

Prototypical presentations

• Stimulant-induced mania: rapid onset, marked irritability and agitation, paranoid features, sympathetic hyperactivity (tachycardia, hypertension, mydriasis), and resolution over 24-72 hours of abstinence in uncomplicated cases. ^10,17
• Antidepressant-induced switch: emerges days to weeks into treatment or after a dose increase, often in a patient previously labeled unipolar depressed; mixed features and irritability are common. ^4,9
• Corticosteroid-induced mania: typically appears within the first two weeks of high-dose therapy, with euphoria, insomnia, racing thoughts, and at higher doses psychosis or delirium. ^6,13
• Dopamine-agonist-induced mania: gradual onset over weeks, often with impulse control disturbances (gambling, hypersexuality) preceding frank mania. ¹⁸

Red flags for medical workup rather than mood-disorder workup:

• Fluctuating attention, disorientation, or visual hallucinations point to delirium with secondary mood symptoms rather than primary mania. ¹³
• Focal neurologic findings, headache, fever, or rapid cognitive decline mandate neuroimaging and broader medical evaluation. ²⁷

The differential is broad because the manic phenotype has many roads in. Working the differential entity by entity prevents the most common error: closing prematurely on primary bipolar I disorder.

Primary bipolar disorders

• Bipolar I and II disorder are diagnosed when manic or hypomanic episodes are not better explained by substance, medication, or another medical condition; a prior episode unrelated to any exposure is decisive evidence for a primary diagnosis. ²⁴
• Antidepressant-emergent mania that persists at full syndromal level beyond the physiological effects of the antidepressant is now considered evidence of a primary bipolar diathesis in DSM-5-TR. ²⁴

Bipolar and related disorder due to another medical condition:

• A mood syndrome attributable to a non-iatrogenic medical cause (for example, hyperthyroidism, Cushing syndrome, multiple sclerosis, frontal stroke, traumatic brain injury, neoplasm, HIV, neurosyphilis) is coded separately from SMIBD. ^24,28
• Hyperthyroidism produces an irritable, anxious, tachycardic picture that overlaps with mania and with stimulant intoxication; thyroid function testing is mandatory. ^27-28
• Cushing syndrome and exogenous hypercortisolism share neuropsychiatric features; the distinction between endogenous Cushing and prescribed corticosteroid as etiology shapes the diagnostic code. ¹³

Delirium

• Delirium with hyperactive features can mimic mania but is distinguished by fluctuating attention, disorientation, and altered level of consciousness. ¹³
• SMIBD criteria explicitly exclude episodes occurring solely during a delirium. ²⁴

Substance intoxication or withdrawal without mood disorder:

• Acute intoxication with stimulants, hallucinogens, or cannabis can produce mood and behavioral changes without meeting threshold for a bipolar-spectrum syndrome; the diagnosis of SMIBD is reserved for the full or near-full manic or hypomanic phenotype with clinically significant impairment. ²⁴
• Alcohol or sedative-hypnotic withdrawal hyperarousal is generally distinguishable by autonomic features and trajectory but can require time to disambiguate. ²³

Schizoaffective disorder and primary psychotic disorders

• Persistent psychotic symptoms outside mood episodes, prominent negative symptoms, or a longitudinal course dominated by psychosis points away from SMIBD. ²⁹

Personality disorders and ADHD

• Cluster B personality features, particularly borderline personality disorder, can produce affective storms misread as hypomania; episodicity, sustained sleep change, and family history help differentiate. ³⁰
• Adult ADHD with stimulant therapy can blur the line: a switch into frank mania on therapeutic stimulant doses is SMIBD; baseline restlessness and distractibility without sustained mood elevation is not. ¹⁷

Mood disorder due to a general medical condition:

• Stroke (especially right hemisphere), frontotemporal dementia, multiple sclerosis, and HIV CNS disease can present with mania-like syndromes and are coded as bipolar and related disorder due to another medical condition rather than SMIBD. ^27-28

The diagnostic workup is structured around two questions: is this a manic syndrome, and if so what caused it. The first is a phenomenology question; the second is a temporal and pharmacologic detective story.

Mandatory history elements

• Onset and trajectory of mood symptoms anchored to the day, dose, and class of any new or escalated agent. ²⁴
• Comprehensive medication review including over-the-counter products, supplements, hormonal preparations, and recent corticosteroid bursts. ⁶
• Substance use history with quantitative timeline: stimulants, cannabis, alcohol, sedative-hypnotics, hallucinogens, MDMA, synthetic cannabinoids and cathinones, anabolic steroids. ^10,21
• Past mood episodes occurring outside any exposure window, family history of mood and substance use disorders, and prior antidepressant-emergent activation. ^4,9
• Sleep history, recent travel and time-zone shifts, and any precipitating medical illness. ¹⁴

Physical and neurologic examination

• Vital signs to identify sympathetic activation and screen for thyrotoxicosis, intoxication, and withdrawal syndromes. ²⁷
• Pupillary findings, tremor, hyperreflexia, and clonus to evaluate for serotonergic toxicity, anticholinergic toxicity, or sympathomimetic intoxication. ^12,27
• Focused neurologic examination to detect findings inconsistent with a primary psychiatric presentation. ²⁷

Laboratory and imaging workup

• Urine drug screen with attention to test panel limitations: standard immunoassays miss many synthetic cathinones, synthetic cannabinoids, MDMA derivatives, and prescription stimulants without targeted assays. ¹⁰
• Serum alcohol level when intoxication is suspected. ²³
• Basic metabolic panel, complete blood count, liver function tests, calcium. ²⁷
• TSH and free T4 for every first-episode mania presentation. ^27-28
• HIV and syphilis serology in patients with risk factors or atypical presentations. ²⁷
• Pregnancy test in patients of reproductive potential before initiating mood stabilizers. ³¹
• Neuroimaging (CT or MRI) for first-episode mania after age 40, focal neurologic findings, or atypical features. ²⁷
• EEG when delirium or seizure is in the differential. ¹³

Validated rating scales

• Young Mania Rating Scale (YMRS) for severity grading at baseline and serial assessment. ³²
• Mood Disorder Questionnaire (MDQ) and the Bipolar Spectrum Diagnostic Scale to screen for an underlying primary bipolar diathesis when antidepressant-induced switch is suspected. ³³
• Confusion Assessment Method (CAM) when delirium remains in the differential. ¹³

What not to order

• Routine genetic testing, advanced neuroimaging, and lumbar puncture are not part of the standard SMIBD workup and should be reserved for specific clinical indications. ²⁷
• Repeat urine drug screening in a patient with a clear and recent positive result rarely changes management. ²⁷

The treatment frame differs from primary mania in one decisive way: the most important intervention is removal or dose reduction of the offending agent. Symptomatic pharmacotherapy is layered on top, calibrated to severity and persistence.

General principles

• Identify and remove the offending agent whenever clinically feasible; for medically necessary agents (corticosteroids in active autoimmune disease, immunosuppression after transplant), partner with the prescribing service to taper or substitute. ^6,34
• Provide a safe, low-stimulation environment and restore sleep; sleep loss is a manicogenic engine that outlasts the original trigger. ¹⁴
• Reassess the diagnosis after a drug-free interval before committing the patient to long-term mood stabilizer therapy; persistence beyond about one month suggests primary bipolar disorder and changes the prognostic frame. ²⁴

Pharmacotherapy

• Strong evidence supports second-generation antipsychotics for acute primary mania, and these agents are commonly recommended for moderate-to-severe SMIBD given phenomenologic overlap, with olanzapine, quetiapine, risperidone, aripiprazole, and ziprasidone in widest use. ^35-36
• Limited evidence specific to SMIBD suggests that short-course antipsychotic therapy at conventional anti-manic doses is generally sufficient and can be tapered as the offending agent clears and symptoms remit. ³⁷
• Lithium and valproate carry strong evidence for primary mania; their role in pure SMIBD is less well-established and they are typically reserved for severe or persistent presentations or when underlying bipolar diathesis is suspected. ^35-36
• Benzodiazepines (lorazepam, clonazepam) are useful adjuncts for agitation, insomnia, and stimulant-related sympathetic hyperactivity; they are first-line for alcohol and sedative-hypnotic withdrawal-related presentations. ^23,38
• For antidepressant-induced mania, discontinue the antidepressant; add a mood stabilizer or antipsychotic for symptom control if the syndrome is severe or persists. ^4-5
• For corticosteroid-induced mania, reduce the steroid dose to the lowest effective level when feasible; second-generation antipsychotics are commonly used for symptomatic control, and lithium has been used both for treatment and as prophylaxis when high-dose steroids are unavoidable. ^6,39
• Avoid initiating an antidepressant during an acute SMIBD episode regardless of any depressive features, given the risk of perpetuating mood instability. ⁴

Psychotherapy

• Substance use disorder treatment, including motivational interviewing and contingency management for stimulant use disorder, is core to relapse prevention when a substance is the trigger. ⁴⁰
• Psychoeducation about the offending agent, early-warning signs, and the rationale for avoidance is essential and is an immediate inpatient or post-discharge intervention. ⁴¹
• Formal mood-disorder psychotherapies (interpersonal and social rhythm therapy, cognitive behavioral therapy for bipolar disorder, family-focused therapy) are reserved for patients who declare a primary bipolar course on follow-up. ⁴¹

Neuromodulation

• Electroconvulsive therapy is rarely required for SMIBD; it is reserved for severe, treatment-refractory, or life-threatening presentations and follows the same indications as for primary mania. ⁴²
• Repetitive transcranial magnetic stimulation has no established role in SMIBD; current bipolar guidelines do not list rTMS as a recommended intervention for acute mania. ^35,37

Adjunctive

• Inpatient admission for safety, observation, detoxification, and a controlled medication-tapering environment is commonly required during the acute phase. ⁴³
• Coordinate with the prescribing specialty (rheumatology, oncology, neurology, infectious diseases, transplant) early; the optimal taper plan is rarely a unilateral psychiatric decision. ³⁴
• Address comorbid medical needs uncovered by the workup, including hypertension, dehydration, and metabolic derangements common in stimulant intoxication. ¹⁰

The evidence base for SMIBD-specific interventions is thin; recommendations largely extrapolate from primary mania trials and case-series experience with the offending agents.

Acute treatment carries the harms of antipsychotic and mood-stabilizer therapy, while the diagnostic frame itself carries the harm of misclassification in either direction. The evidence base is also small enough to demand humility in any recommendation.

Common adverse effects

• Second-generation antipsychotics: sedation, weight gain, metabolic syndrome, akathisia, extrapyramidal symptoms, prolactin elevation, and QT prolongation. ³⁵
• Lithium: tremor, polyuria, weight gain, gastrointestinal upset, cognitive blunting, and thyroid suppression. ⁴⁴
• Valproate: gastrointestinal upset, weight gain, alopecia, tremor, and thrombocytopenia. ⁴⁵
• Benzodiazepines: sedation, ataxia, anterograde amnesia, paradoxical disinhibition. ³⁸

Serious or rare adverse effects

• Neuroleptic malignant syndrome with any antipsychotic, particularly when combined with sympathomimetic intoxication or dehydration. ⁴⁶
• Lithium toxicity at supratherapeutic levels, with risk amplified by dehydration, NSAIDs, ACE inhibitors, and thiazide diuretics. ⁴⁴
• Valproate-induced hepatotoxicity, pancreatitis, hyperammonemic encephalopathy. ⁴⁵
• Major teratogenic risk with valproate (neural tube defects, neurodevelopmental effects); meaningful but lower teratogenic risk with lithium (cardiac malformations including Ebstein anomaly historically reported, with more recent data suggesting smaller absolute risk than originally estimated). ^31,47

Monitoring burden, withdrawal, and discontinuation

• Lithium requires periodic levels, renal function, and thyroid monitoring throughout therapy. ⁴⁴
• Valproate requires periodic LFTs, complete blood count, and consideration of ammonia in selected presentations. ⁴⁵
• Antipsychotic monitoring includes weight, lipids, glucose or HbA1c, and QTc when clinically relevant. ³⁵
• Abrupt discontinuation of benzodiazepines after sustained use risks withdrawal seizures; taper deliberately. ³⁸

Limitations of the evidence

• No large RCTs target SMIBD specifically; recommendations rely on extrapolation, case series, and clinical consensus. ³⁷
• Most observational cohorts conflate substance-induced and primary bipolar episodes at baseline, biasing prevalence and outcome estimates. ^3,9
• Antidepressant-emergent mania literature is heterogeneous in diagnostic thresholds (subsyndromal activation versus full syndromal mania), limiting comparability across studies. ⁴
• Long-term follow-up data on SMIBD-to-bipolar conversion rates come largely from antidepressant-induced and stimulant-induced cohorts and may not generalize to other agents. ^9,17

Demographic and comorbidity context shapes both the differential and the treatment plan. The headline issue across populations is medication safety in the setting of acute symptomatic instability.

Pediatric and adolescent

• Stimulant therapy for ADHD can produce manic-spectrum activation; differentiating SMIBD from emerging primary pediatric bipolar disorder requires careful longitudinal observation. ^17,48
• Adolescent substance exposures, including prescription stimulant misuse and synthetic cannabinoids, are common precipitants in this age group. ^21,48
• Antidepressant-induced switch carries particular weight in pediatric depression given the higher rate of latent bipolarity and the FDA black-box warning context. ^4,48

Geriatric

• A first manic episode after age 50 carries a high pretest probability of a secondary cause (medication, neurologic disease, metabolic derangement) and warrants neuroimaging and broad medical workup. ^27,49
• Polypharmacy multiplies the risk of medication-induced presentations; a careful brown-bag review including supplements is high-yield. ⁴⁹
• Lithium pharmacokinetics shift with age and renal function; lower target levels and slower titration apply. ⁴⁹

Perinatal

• Pregnancy and the postpartum period are high-risk windows for primary mood episodes; distinguishing antidepressant-induced switch in this period from postpartum bipolar onset has direct prognostic and treatment implications. ⁵⁰
• Lithium and valproate both carry teratogenic concerns; valproate is generally avoided in patients of childbearing potential, and lithium use in pregnancy involves an individualized risk-benefit discussion with obstetric input. ^31,47
• Pregnancy itself is associated with substance use changes; corticosteroid use for obstetric indications (antenatal steroids) is generally short-course and rarely produces SMIBD but warrants monitoring. ⁶

Comorbid medical illness

• Patients on chronic high-dose corticosteroids for autoimmune disease, transplant, or oncologic indications represent the largest cohort of iatrogenic SMIBD; coordinate taper with the prescribing service. ^6,34
• HIV, traumatic brain injury, and demyelinating disease independently raise the risk of secondary mania; the etiologic code shifts to bipolar and related disorder due to another medical condition when those conditions are causal. ^27-28
• Patients with Parkinson disease on dopaminergic agents are at elevated risk for impulse control disorders and dopaminergic-induced mania. ¹⁸

Comorbid substance use

• Stimulant use disorder is the most common substance-related driver; integrated treatment combining behavioral therapy and addiction-focused care is essential. ⁴⁰
• Polysubstance presentations are the rule rather than the exception in emergency departments; treat the acute syndrome, identify the dominant agent, and plan a single coordinated taper or detoxification path. ¹⁰

Cultural considerations

• Substance availability varies by region and demographic; clinicians should maintain awareness of locally prevalent agents (kratom, khat, novel psychoactive substances) and update workup panels accordingly. ²¹
• Stigma around substance use can lead patients and families to underreport exposure; framing questions non-judgmentally improves diagnostic yield. ⁴⁰

Most SMIBD episodes resolve once the agent is removed and the patient is supported through the acute phase. The longer-term question is whether the episode unmasked a primary bipolar diathesis.

Acute course

• Stimulant-induced episodes typically resolve within 24-72 hours of abstinence in uncomplicated cases. ^10,17
• Corticosteroid-induced episodes typically remit within one to two weeks of dose reduction or discontinuation. ⁶
• Antidepressant-induced switch usually resolves within days to weeks of antidepressant discontinuation, though residual mood instability can persist. ⁴

Conversion to primary bipolar disorder

• Among patients with antidepressant-emergent mania, longitudinal cohorts suggest a substantial fraction (with estimates varying widely across studies) ultimately meet criteria for primary bipolar disorder, particularly those with bipolar family history or early-onset depression. ^9,15
• Among patients with stimulant-induced mood episodes, follow-up studies suggest a meaningful minority go on to declare a primary mood disorder. ^17,51
• Persistence of full syndromal mania more than about one month after the offending agent is removed is itself reclassifying evidence under DSM-5-TR. ²⁴

Suicide risk

• Bipolar-spectrum disorders broadly carry elevated suicide risk, and acute mixed or dysphoric mania is a particularly high-risk state regardless of etiology. ⁵²
• Active stimulant intoxication, post-stimulant crash, and steroid-induced dysphoric mania each carry distinct, elevated suicide risk profiles requiring active screening and safety planning. ^52-53

Functional outcome and mortality

• Functional outcomes in pure SMIBD where the agent is identified and removed are generally favorable. ³⁷
• Comorbid substance use disorder is the dominant driver of long-term morbidity, mortality, and recurrence in stimulant-related cases. ⁴⁰

Most SMIBD presentations come through emergency departments and acute psychiatric units. The decisions are operational: where does the patient go, who taps the brakes on the offending agent, and how do you secure safety.

Hospitalization criteria

• Inability to maintain safety, severe agitation, psychosis, suicidality or homicidality, severe sleep loss, or medical instability warrant inpatient psychiatric admission. ⁴³
• Active stimulant intoxication with hemodynamic instability, hyperthermia, or rhabdomyolysis warrants medical stabilization first, often in an ED observation or medical unit. ¹⁰
• Steroid-induced mania in a medically complex patient is often best managed on a medical floor with psychiatric consultation, given the underlying medical illness. ¹³

Suicide risk markers

• Mixed features, agitation, command hallucinations, hopelessness, recent loss, and active substance use compound risk. ⁵²
• Document a structured risk assessment that includes ideation, intent, plan, access to means, protective factors, and prior attempts. ⁵²

Agitation management

• Verbal de-escalation and environmental modification are first steps; offer oral medication before parenteral when feasible. ³⁸
• For severe agitation, options include intramuscular olanzapine, haloperidol with lorazepam, or droperidol (where available); avoid combining intramuscular olanzapine with parenteral benzodiazepines because of respiratory and hypotensive risk. ^38,54
• Address the underlying physiology: cool the hyperthermic stimulant-intoxicated patient, hydrate, correct electrolytes. ¹⁰

Safety-relevant comorbid presentations

• Serotonin toxicity from drug-drug interactions can mimic agitation and hyperthermia; recognize the triad of mental status change, autonomic hyperactivity, and neuromuscular signs (clonus, hyperreflexia). ¹²
• Anticholinergic toxicity from polypharmacy (antihistamines, tricyclics, benztropine) presents with agitation, hyperthermia, dry skin, and mydriasis and is treated supportively, with physostigmine reserved for selected severe cases. ²⁷

The diagnostic category sits at a productive disagreement between clinical pragmatism and nosologic precision. Several debates are clinically relevant.

Where the line sits between SMIBD and primary bipolar disorder:

• The DSM-5-TR rule that antidepressant-emergent mania persisting beyond the physiological effects of the antidepressant counts as primary bipolar disorder departs from earlier DSM-IV practice and remains contested in the literature. ^4,24
• Critics argue this rule risks overdiagnosing primary bipolar disorder in patients whose brittle response to serotonergic agents may not reflect a lifelong cycling course. ⁹

How long is "more than one month":

• The persistence threshold is a clinical heuristic rather than a tightly validated cutoff; some experts recommend longer washout windows in patients with prolonged-half-life agents (fluoxetine and norfluoxetine) or anabolic steroids. ^4,24

Stimulant-induced mania and the unmasking question

• Whether stimulant-induced mania reflects a latent bipolar diathesis being unmasked, a phenocopy without prognostic implication, or both, remains an open question; cohort follow-up data suggest a heterogeneous picture with subgroups going either way. ^17,51

Antidepressant safety in unipolar depression

• The absolute rate of antidepressant-induced mania in non-bipolar depressed patients is low but not zero; whether this represents undiagnosed bipolar diathesis or a true antidepressant-specific effect is debated. ^4-5
• Some experts recommend baseline bipolar screening (MDQ, family history) for every patient initiated on an antidepressant, though high-quality evidence to mandate this universally is lacking. ³³

Long-term mood-stabilizer prophylaxis after a single SMIBD episode:

• Whether to continue mood stabilizer therapy beyond the acute episode in a patient with a single SMIBD presentation, without prior mood episodes, is a judgment call; current guidance favors observation with close follow-up rather than indefinite prophylaxis unless a primary diagnosis declares itself. ³⁷

Regulatory and scheduling differences

• Several agents associated with iatrogenic mania (corticosteroids, dopamine agonists, isoniazid) carry no scheduling restrictions and are widely prescribed without psychiatric pre-screening, leaving recognition to the treating non-psychiatric service. ^6,18
• Off-label and over-the-counter agents (decongestants, herbal stimulants, supplements containing yohimbine or sibutramine analogs in some markets) are underrepresented in case series and likely underrecognized as triggers. ²¹

• SMIBD is diagnosed when a manic or hypomanic syndrome emerges during or shortly after substance, medication, or toxin exposure and is judged a direct physiological consequence of that agent. ²⁴
• Persistence of a full manic syndrome for more than approximately one month after the offending agent is removed reclassifies the diagnosis as primary bipolar disorder under DSM-5-TR. ²⁴
• Antidepressant-emergent mania that persists beyond the physiological effects of the antidepressant counts as primary bipolar disorder in DSM-5-TR. ²⁴
• Common offending agents include stimulants, corticosteroids, antidepressants, dopamine agonists, isoniazid, efavirenz, anabolic steroids, and interferon-alpha. ^{6,10,18-19,22}
• Family history of bipolar disorder is the strongest single predictor of antidepressant-emergent mania. ^4,9
• Corticosteroid-induced mood symptoms are dose-dependent, with the highest risk above prednisone-equivalent 40 mg/day. ⁶
• A first manic episode after age 40 should prompt neuroimaging and a broader medical workup. ²⁷
• TSH and free T4 are mandatory in any first-episode mania workup. ^27-28
• Stimulant-induced mania typically resolves within 24-72 hours of abstinence in uncomplicated cases. ^10,17
• Avoid initiating or continuing antidepressants during an acute manic episode, including SMIBD. ⁴
• Removal or dose reduction of the offending agent is the first-line intervention; symptomatic pharmacotherapy is layered on top. ³⁷
• Second-generation antipsychotics are commonly used for acute symptomatic control of SMIBD, extrapolating from primary mania evidence. ³⁵
• Lithium has been used both for treatment and as prophylaxis in patients on unavoidable high-dose corticosteroids. ³⁹
• ICD-11 codes substance-induced mood disorders within each substance class rather than within the mood disorders chapter. ²⁵
• SMIBD is excluded if symptoms occur exclusively during a delirium. ²⁴

No external funding. No conflicts of interest declared. Peer-review status: pending.